Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype have not been systematically described. Methods: In...

Full description

Bibliographic Details
Main Authors:	Noura J. Choudhury, MD, Jaime L. Schneider, MD, PhD, Tejas Patil, MD, Viola W. Zhu, MD, PhD, Debra A. Goldman, MS, Soo-Ryum Yang, MD, Christina J. Falcon, MPH, Andrew Do, BS, Yunan Nie, MD, Andrew J. Plodkowski, MD, Jamie E. Chaft, MD, Subba R. Digumarthy, MD, Natasha Rekhtman, MD, PhD, Maria E. Arcila, MD, Alexia Iasonos, PhD, Sai-Hong I. Ou, MD, PhD, Jessica J. Lin, MD, Alexander Drilon, MD
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	JTO Clinical and Research Reports
Subjects:	Non–small cell lung cancer ROS1 fusion Immune checkpoint inhibitors Tumor mutational burden PD-L1
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364321000461

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000461

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

Internet

Similar Items